TG Therapeutics, Inc.
BRIUMVI (ublituximab-xiiy)
relapsing forms of multiple sclerosis (RMS)
Resolved
41days ago
Phase 3 readout · May 27, 2026
What's at stake
Phase 3 trial results for BRIUMVI (ublituximab-xiiy) in relapsing forms of multiple sclerosis (RMS) are due May 27, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“On May 27, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiat”